GENOR BIOPHARMA DL-00002 Market Cap ($93.97 Million)
Market Cap & Net Worth: GENOR BIOPHARMA DL-00002 (67N0)
GENOR BIOPHARMA DL-00002 market cap. GENOR BIOPHARMA DL-00002 (F:67N0) has a market capitalization of $93.97 Million (€80.38 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #19256 globally and #1768 in its home market, demonstrating a 0.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENOR BIOPHARMA DL-00002's stock price €0.17 by its total outstanding shares 524624608 (524.62 Million). Also see GENOR BIOPHARMA DL-00002 (67N0) cash flow conversion for how efficiently the company converts equity into cash flow.
GENOR BIOPHARMA DL-00002 Market Cap History (2020–2026)
GENOR BIOPHARMA DL-00002 market cap history from 2020 to 2026. Data shows change from $1.12 Billion to $106.72 Million (-37.17% CAGR). Check latest GENOR BIOPHARMA DL-00002 stock price today for real-time trading data and today's change.
GENOR BIOPHARMA DL-00002 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENOR BIOPHARMA DL-00002's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GENOR BIOPHARMA DL-00002 (67N0) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.57x
GENOR BIOPHARMA DL-00002's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $172.96 Million | $15.93 Million | -$730.21 Million | 10.86x | N/A |
| 2024 | $116.53 Million | $206.23 Million | -$51.28 Million | 0.57x | N/A |
Competitor Companies of 67N0 by Market Capitalization
Companies near GENOR BIOPHARMA DL-00002 in the global market cap rankings as of November 4, 2026. Also see balance sheet size of GENOR BIOPHARMA DL-00002 for a full breakdown of the balance sheet.
Key companies related to GENOR BIOPHARMA DL-00002 by market ranking:
- Investeringsselskabet Luxor A/S (CO:LUXOR-B): Ranked #19247 globally with a market cap of $94.23 Million USD ( Dkr602.25 Million DKK).
- NextEye Co. Ltd (KQ:137940): Ranked #19248 globally with a market cap of $94.22 Million USD ( ₩139.03 Billion KRW).
- Leadtrend Technology Corp (TW:3588): Ranked #19257 globally with a market cap of $93.95 Million USD ( NT$2.98 Billion TWD).
- Gelecek Varlik Yonetimi AS (IS:GLCVY): Ranked #19258 globally with a market cap of $93.93 Million USD ( TL4.19 Billion TRY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #19247 | Investeringsselskabet Luxor A/S | CO:LUXOR-B | $94.23 Million | Dkr730.00 |
| #19248 | NextEye Co. Ltd | KQ:137940 | $94.22 Million | ₩1845.00 |
| #19257 | Leadtrend Technology Corp | TW:3588 | $93.95 Million | NT$48.10 |
| #19258 | Gelecek Varlik Yonetimi AS | IS:GLCVY | $93.93 Million | TL30.02 |
Market Capitalization of GENOR BIOPHARMA DL-00002 (2020–2026)
Market capitalization of GENOR BIOPHARMA DL-00002 from 2020 to today. Between 2020 and today, GENOR BIOPHARMA DL-00002's market cap moved from $1.12 Billion to $ 106.72 Million, with a yearly change of -37.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €106.72 Million | -48.21% |
| 2025 | €206.08 Million | +76.84% |
| 2024 | €116.53 Million | +57.02% |
| 2023 | €74.21 Million | -57.09% |
| 2022 | €172.96 Million | -64.65% |
| 2021 | €489.32 Million | -56.40% |
| 2020 | €1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of GENOR BIOPHARMA DL-00002 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $93.97 Million USD |
| MoneyControl | $93.97 Million USD |
| MarketWatch | $93.97 Million USD |
| marketcap.company | $93.97 Million USD |
| Reuters | $93.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical tri… Read more